The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well-controlled studies in treating ocular symptoms associated